CNS PHARMACEUTICALS, INC. (CNSP): Price and Financial Metrics


CNS PHARMACEUTICALS, INC. (CNSP): $2.01

0.03 (+1.52%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CNSP Stock Price Chart Interactive Chart >

Price chart for CNSP

CNSP Price/Volume Stats

Current price $2.01 52-week high $4.46
Prev. close $1.98 52-week low $1.59
Day low $1.96 Volume 72,800
Day high $2.01 Avg. volume 1,027,339
50-day MA $1.99 Dividend yield N/A
200-day MA $2.18 Market Cap 50.97M

CNS PHARMACEUTICALS, INC. (CNSP) Company Bio


CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.


CNSP Latest News Stream


Event/Time News Detail
Loading, please wait...

CNSP Latest Social Stream


Loading social stream, please wait...

View Full CNSP Social Stream

Latest CNSP News From Around the Web

Below are the latest news stories about CNS Pharmaceuticals Inc that investors may wish to consider to help them evaluate CNSP as an investment opportunity.

Lyophilization Services for Biopharmaceuticals Market - CNS Pharmaceuticals, Jubilant HollisterStier LLC, Lyophilization Technology, Inc. (LTI), GILYOS GmbH, Lyophilization Services of New England, Inc., Piramal Pharma Solutions Inc.

Lyophilization Services for Biopharmaceuticals Market Report 2020-2027 includes a comprehensive analysis of the present Market. The report starts with the basic Lyophilization Services for Biopharmaceuticals industry overview and then goes into each and every detail. Lyophilization Services for Biopharmaceuticals Market Report

OpenPR | June 7, 2021

GBM Brain Cancer Sorting Development Latest Bit of Good News for Patients as CNS Pharmaceuticals (NASDAQ: CNSP) Develops Drug Trial

Biopharmaceutical developer CNS Pharmaceuticals is working on ways to improve overall survivability for glioblastoma multiforme (GBM) brain cancer patients GBM is considered to be an incurable brain cancer that usually only leaves patients about 15 months to live once they are diagnosed, prompting research efforts to improve patients responses to therapeutic approaches A recent study Continue reading "GBM Brain Cancer Sorting Development Latest Bit of Good News for Patients as CNS Pharmaceuticals (NASDAQ: CNSP) Develops Drug Trial" The post GBM Brain Cancer Sorting Development Latest Bit of Good News for Patients as CNS Pharmaceuticals (NASDAQ: CNSP) Develops Drug Trial appeared first on NetworkNewsWire .

NetworkNewsWire | May 25, 2021

CNS Pharmaceuticals Begins Enrollment, Screening Brain Cancer Study With Berubicin

CNS Pharmaceuticals Inc (NASDAQ: CNSP ) has opened enrollment for its Phase 2 study evaluating its lead candidate, Berubicin, for recurrent Glioblastoma Multiforme (GBM). The company intends to enroll approximately 210 subjects. The trial includes adult patients with recurrent glioblastoma multiforme after the Full story available on Benzinga.com

Benzinga | May 19, 2021

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin

Study to evaluate efficacy and safety of Berubicin in the treatment of adult recurrent Glioblastoma Multiforme (GBM), one of the most aggressive types of brain cancer Interim analysis of trial when 50% of planned subjects reach 6 months in study

BioSpace | May 18, 2021

Did CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Insiders Buy Up More Shares?

It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

Yahoo | May 13, 2021

Read More 'CNSP' Stories Here

CNSP Price Returns

1-mo 12.29%
3-mo -26.37%
6-mo -12.23%
1-year -18.62%
3-year N/A
5-year N/A
YTD 12.92%
2020 -54.94%
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7169 seconds.